These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11498766)

  • 1. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line.
    Leonetti C; Biroccio A; Benassi B; Stringaro A; Stoppacciaro A; Semple SC; Zupi G
    Cancer Gene Ther; 2001 Jun; 8(6):459-68. PubMed ID: 11498766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
    Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
    Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
    Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
    Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
    Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
    Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.
    Ginobbi P; Geiser TA; Ombres D; Citro G
    Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
    Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
    J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
    Iversen PL; Arora V; Acker AJ; Mason DH; Devi GR
    Clin Cancer Res; 2003 Jul; 9(7):2510-9. PubMed ID: 12855625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin.
    Pastorino F; Mumbengegwi DR; Ribatti D; Ponzoni M; Allen TM
    J Control Release; 2008 Feb; 126(1):85-94. PubMed ID: 18166243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
    Leonetti C; Biroccio A; D'Angelo C; Semple SC; Scarsella M; Zupi G
    Prostate; 2007 Sep; 67(13):1475-85. PubMed ID: 17654511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
    Gokhale PC; Zhang C; Newsome JT; Pei J; Ahmad I; Rahman A; Dritschilo A; Kasid UN
    Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model.
    Sekhon HS; London CA; Sekhon M; Iversen PL; Devi GR
    Lung Cancer; 2008 Jun; 60(3):347-54. PubMed ID: 18096271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C; Wellham LL
    Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
    Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
    J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Telomerase antisense inhibition and chemotherapeutic combination treatments for the proliferation of endometrial cancer in vitro and in vivo].
    Chen XJ; Zheng W; Chen LL; Chen ZB; Wang SQ
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1721-5. PubMed ID: 15569435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
    Mui B; Raney SG; Semple SC; Hope MJ
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas.
    Hwang TL; Lee WR; Hua SC; Fang JY
    J Dermatol Sci; 2007 Apr; 46(1):11-20. PubMed ID: 17267180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
    Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.